pHLIP-SS-DOX, a novel peptide-drug conjugate targeting to tumor cells

• 作 者: QinSong;XingxingChuan;BinlongChen;JingSun;BingHe;WenbingDai;HuaZhang;XueqingWang;QiangZhang;
• 机 构: State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking Univer
• 出 处: 2014年中国药物制剂大会——中国药学会药剂专业委员会年会、第六届亚洲阿登制药技术研讨会暨国际控释协会中国分会年会
• 发表日期: 2014年期

　　The therapeutic efficacy of doxorubucin (DOX) in cancer treatment is limited by two rain factors, systemic toxicity resulted from the nonspecific transportation and the emergence of tumor resistance.To overcome these hurdles, we used a peptide called pH low insertion peptide (pHLIP) to couple with DOX through disulfide bond and developed a pHLIP-SS-DOX conjugate.